The Wall Street Journal

Sept. 28, 2021, 3:20 a.m. EDT

Merck nears deal for rare-disease-drug maker Acceleron

By Cara Lombardo and Ben Dummett

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business.

The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don’t fall apart, the people said.

Should a deal come together, it would be one of Merck’s (NYS:MRK) biggest and represent a bet on the treatments for the respiratory and blood diseases that Acceleron (NAS:XLRN) specializes in.

Merck appears to have beaten out other potential suitors for Acceleron including Bristol Myers Squibb Co., (NYS:BMY) which already owns a big stake in the company.

An expanded version of this story is available at

Link to MarketWatch's Slice.